Key result
New oral anticoagulants (dabigatran, rivaroxaban, and apixaban) appear noninferior, and sometimes superior, to warfarin for efficacy and safety in patients with atrial fibrillation.
Why the study?
Do new oral anticoagulants (dabigatran, rivaroxaban, apixaban) provide noninferior or superior efficacy and safety compared to warfarin in patients with atrial fibrillation?
Do new oral anticoagulants (dabigatran, rivaroxaban, apixaban) provide noninferior or superior efficacy and safety compared to warfarin in patients with atrial fibrillation?
New oral anticoagulants (dabigatran, rivaroxaban, apixaban) offer a promising, noninferior or superior alternative to warfarin for atrial fibrillation, though switching is not universally recommended.
May support NOAC preference over warfarin in select AF patients; leaves open need for prospective validation in diverse populations.
Vitamin K antagonists (VKAs) were, until recently, the only option for chronic anticoagulation in patients with atrial fibrillation. Three new oral anticoagulants have been tested for this indication in recent randomized trials: dabigatran, rivaroxaban, and apixaban. They offer the promise of consistent effect without the need for monitoring drug levels. Overall, efficacy and safety appear to be noninferior, and in some instances superior, to warfarin. However, the new drugs have their downsides, and switching from warfarin is not recommended for all patients. This review focuses on the available evidence and attempts to provide guidance to clinicians in the field.
No takes yet. Share an insight, caveat, or question.
Mantha et al. (2012) conducted a review in Atrial Fibrillation. New oral anticoagulants (dabigatran, rivaroxaban, apixaban) vs. Warfarin (Vitamin K antagonists) was evaluated. New oral anticoagulants (dabigatran, rivaroxaban, and apixaban) appear noninferior, and sometimes superior, to warfarin for efficacy and safety in patients with atrial fibrillation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: